Arrowhead Pharmaceuticals, Inc.

ARWR · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.7%

Institutions85.6%

Public / Other

Income Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	$829.45M	$3.55M	$240.74M	$243.23M	$138.29M	$87.99M	$168.80M	$16.14M	$31.41M	$158333
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$98.35M	-$601.08M	-$205.00M	-$178.51M	-$149.04M	-$93.16M	$61.19M	-$55.94M	-$37.00M	-$81.74M
Operating income as a percentage of revenue.	11.9%	-16927.1%	-85.2%	-73.4%	-107.8%	-105.9%	36.3%	-346.5%	-117.8%	-51627.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$31.75M	-$10.20M	-$4.00M	-$431000	-$140.85M	-$84.55M	$67.97M	-$54.45M	-$34.38M	-$81.72M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.01	$-5.00	$-1.92	$-1.00	$-1.36	$0.00	$0.00	$0.00	$0.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.01	$-5.00	$-1.92	$-1.00	$-1.36	$0.00	$0.00	–	–	–

Balance Sheet

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$226.50M	$102.70M	$110.90M	$108.00M	$184.40M	$143.60M	$221.80M	$30.13M	$24.84M	$85.37M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.39B	$1.14B	$765.55M	$691.94M	$710.15M	$522.50M	$349.85M	$111.61M	$104.02M	$128.18M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	–	$223820	$208506	$194310
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$466.05M	$185.44M	$271.34M	$398.52M	$408.82M	$461.78M	$244.59M	$95.80M	$81.42M	$95.58M

Cash Flow Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$179.55M	-$462.85M	-$153.89M	-$136.13M	$171.22M	-$95.40M	$173.03M	-$47.22M	-$23.94M	-$64.43M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$22.70M	$141.47M	$176.74M	$52.78M	$23.57M	$11.95M	$12.00M	$1.42M	$7.92M	$3.86M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$156.85M	-$604.32M	-$330.63M	-$188.91M	$147.66M	-$107.35M	$161.03M	-$48.64M	-$31.86M	-$68.29M

	You	Peer avg
P/E	–	75.7
Revenue Growth	+171.0%	+26.1%
ROE	-55.2%	6.7%

Arrowhead Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Income Statement

Balance Sheet

Cash Flow Statement

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison